Brought to you by 
Micrologix licenses antimicrobials from U. of Br. Columbia
13 Jul 1999
Executive Summary
Micrologix Biotech Inc. (peptide technology to enhance antibiotics) has acquired worldwide, exclusive rights to antimicrobial technology developed by researchers at the University of British Columbia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Micrologix licenses antimicrobials from U. of Br. Columbia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice